Oxford Biomedica - where's the 'huge value creation' then?

The GenVec treatment, if successful, will help validate gene therapy in general, said John W. Holaday, founding partner of Montgomery Pacific Group, a Bethesda investment group.

‘‘There is certainly some interesting data now,” Holaday said. ‘‘We in biotech applaud innovative success in gene therapy.”

Final clinical trials will be quite expensive, he said, but ‘‘by then hopefully [GenVec] will have a strategic market.”